Ten Years of MS Data Make Delay Harder to Defend
A decade of OPERA follow-up shows durable relapse and disability control with ocrelizumab, while patients who started high-efficacy therapy later never fully caught up. The…
Ten Years of MS Data Make Delay Harder to Defend
Severe preeclampsia may leave a measurable signature in the fetal heart
IPM Brief – Issue 37 | The body has a veto
One Blood Test for 50 Cancers Is Closer to the FDA. The Evidence Is Still Fighting Back.
Schizophrenia Gets a Five-Day Brain-Stimulation Signal
The Mystery Patient Found The Gaps
Europe is building the infrastructure to decide which cardiovascular AI can be trusted
Explore by disease area
Cardiology
Mapping prevention, diagnostics and access pathways for cardiovascular care.
Cardiometabolic
Tracking risk, prevention and access in metabolic and vascular health.
Eye Disease
Following diagnostics, treatment access and equity in vision care.
Infectious disease
Tracking diagnostics, resistance, prevention and access across infection pathways.
Neurology
Mapping early diagnosis, biomarkers and access in brain health.
Oncology
Following testing, treatment access and equity across cancer pathways.
Alerts
See all →
Skin Cancer AI Has Crossed a Line: It Is Discharging Patients on Its Own
Preparedness Finally Has Capital
Precision Oncology Has a Scale Problem
Epilepsy Treatment Does Not Have to End Breastfeeding
Food Safety Gets A Political Upgrade
Dengue Policy Goes Regional
ESR1 Resistance Is Becoming a Treatment Pathway, Not a Footnote
AMR Plans Without Money
CLL Just Moved a Noncovalent BTK Inhibitor Into First Line
Myeloma Pain May Need 4 Gy, Not a Treatment Odyssey
Signals
See all →
One Blood Test for 50 Cancers Is Closer to the FDA. The Evidence Is Still Fighting Back.
Schizophrenia Gets a Five-Day Brain-Stimulation Signal
Severe preeclampsia may leave a measurable signature in the fetal heart
A prospective study of 224 pregnancies found that severe preeclampsia was associated with measurable changes in fetal cardiac performance and Doppler parameters, alongside earlier delivery,…
Playbook
See all →
IPM Brief – Issue 37 | The body has a veto
By Denis Horgan, Secretary General of the International Alliance for Personalised Medicine
IPM Brief – Issue 36 | The system saw it coming
By Denis Horgan, Secretary General of the International Alliance for Personalised Medicine
IPM Brief – Issue 35 | The care contract is being rewritten
By Denis Horgan, Secretary General of the International Alliance for Personalised Medicine
IPM Brief – Issue 34 | The switchboard is political
By Denis Horgan, Secretary General of the International Alliance for Personalised Medicine
IPM Brief – Issue 33 | Who Regulates the Future?
By Denis Horgan, Secretary General of the International Alliance for Personalised Medicine
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
By subscribing, you agree to receive updates from IPM Alliance. You can unsubscribe at any time. For more information, please see our Privacy Policy.
